Peptech in cancer JV
01 December, 2003 by Melissa TrudingerPeptech (ASX:PTD) has entered into a joint venture with University of Sydney spin-off Biosceptre International to develop a range of diagnostic and therapeutic products based on a specific cancer marker expressed in a broad range of human cancers including skin, prostate, breast, bowel and uterine cancers.
The dark side of global warming
28 November, 2003 by Graeme O'NeillGlobal warming is making nights warmer around the globe and from pole to pole, and will have major effects on plant photosynthesis and productivity, according to Columbia University plant physiologist Dr Kevin Griffin.
BresaGen to spin off cell therapy business
28 November, 2003 by Melissa TrudingerBresaGen (ASX:BGN) is likely to become a holding company with stakes in several businesses, including a new stem cell company formed by the merger of BresaGen's cell therapy division with San Diego stem cell company CyThera, CEO John Smeaton told the company's AGM yesterday.
Norwood expects revenues from next month
28 November, 2003 by Melissa TrudingerNorwood Abbey (ASX:NAL) executive chairman Peter Hansen told shareholders at the company's AGM yesterday that the first revenues from the company's laser assisted drug delivery device would flow into the company in late December or early January.
AgGenomics ties up A2 milk DNA profiling deal
27 November, 2003 by Melissa TrudingerAgGenomics, a joint venture company owned by Melbourne-based Genetic Technologies (ASX:GTG) and the Victorian government, has been selected as the exclusive Australian provider of DNA profiling services for the selection of A2 dairy cattle for New Zealand company A2 Corporation.
BioAngels makes first local investment
27 November, 2003 by Melissa TrudingerMembers of South Australia's BioAngels have made their first investment into the South Australian bioscience sector, selecting Australian Orthopaedic Innovations from more than 20 applications.
Rockeby Biomed readies for IPO
26 November, 2003 by Melissa TrudingerDiagnostics company Rockeby Biomed is readying itself to float on the ASX in a back door listing through Carbine Corporation.
pSvida acquisition opens diagnostic pathway
26 November, 2003 by Melissa TrudingerPerth-based nanomaterials specialist pSivida (ASX:PSD) has acquired the rights to use porous silicon mirror technology from German research agency Forschungszentrum Julich.
BresaGen sells its catheter technology
26 November, 2003 by Melissa TrudingerBresaGen (ASX:BGN) has assigned its cell delivery catheter licenses to North American company NexGen Technologies for about $380,000 plus a four per cent share in NexGen.
BioDiem readies for December IPO
25 November, 2003 by Melissa TrudingerMelbourne biotechnology company BioDiem has lodged a prospectus with ASIC for an AUD$10 million float opening on December 4.
Phenomix expands its Australian operations
25 November, 2003 by Melissa TrudingerPhenomix, based jointly in San Diego and Canberra, has appointed experienced biotechnology executive Dr Julie Cherrington as president of operations to oversee its Australian activities as it moves into pre-clinical and clinical programs.
Cochlear names new CEO
25 November, 2003 by Melissa TrudingerCochlear has named ResMed executive VP Dr Chris Roberts as its new CEO, replacing Jack O'Mahony.
Polartechnics raises $11.25m; plans global push
24 November, 2003 by Melissa TrudingerSydney-based medical device firm Polartechnics (ASX:PLT) has used a combination of a share placement and a share purchase plan to raise AUD$11.25 million to expand its global sales and marketing efforts and refine its production processes.
Solbec gets nod on cancer drug trial
24 November, 2003 by Melissa TrudingerPerth biotech Solbec Pharmaceuticals (ASX:SBP) has received approval to commence a Phase I clinical trial on its lead cancer therapeutic SBP002.
Vics pledge $1.5m to wallaby genome project
24 November, 2003 by Melissa TrudingerVictoria's state government has pledged AUD$1.5 million funding for a wallaby genome project, which needs around $6 million to match US National Institutes of Health funding to proceed.
